|Mol. mass||147 kDa|
| (what is this?)
Zanolimumab (expected trade name HuMax-CD4) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma. The drug is currently undergoing Phase II trials.
- Genmab initiates Phase II Study with HuMax-CD4
- Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ClinicalTrials.gov NCT00042406 Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker
- "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|